Gemina Laboratories Ltd. Announces Strategic Update and Future Outlook

Gemina Laboratories Ltd. has provided an update concerning its strategic focus and outlook for 2024 and beyond. The company has made significant progress in developing commercial partnerships, aiming to enhance revenue through product development, licenses, and services. 2024 will witness the completion of their protein production facility to support an increasing customer base, with a broader focus on respiratory diagnostics and potential expansion into clinical and veterinary diagnostics.

The company has improved lateral flow test sensitivity for Covid-19, developing solutions applicable to a wider diagnostic sector. Gemina's technology has reduced non-specific binding and enabled nitrocellulose replacement in rapid test designs. This innovation underpins their assay platforms such as the Legio-X covid test and the Universal Test Architecture. Despite the challenging diagnostics industry climate in 2023, Gemina plans to drive revenue through licensing deals in 2024, leveraging their technology's validation by external customers.

Gemina's innovation extends to addressing biotin interference in diagnostic tests, a growing concern for regulators and diagnostics companies. They have developed solutions to mitigate this interference, planning to further develop and deploy these solutions in 2024. The outlook for Gemina includes expanding their licensable asset base, developing strategic partnerships, and enhancing their production capabilities with a new facility. The company is also working towards addressing the global health threat of Tuberculosis (TB) and exploring the wellness market for additional opportunities. Gemina's shares are set to be listed on the United States OTCBB marketplace, increasing their exposure to international investors.